In this episode [13.42], Medicom’s correspondent covers 6 presentations from the Digestive Disease Week (DDW 2024), held in Washington DC, USA, from 18-21 May 2024.
The topics discussed are:
- GALAXI 2 & 3: Guselkumab proves efficacy in Crohn’s disease
Guselkumab demonstrated superior short and long-term clinical and endoscopic outcomes compared with ustekinumab and placebo in participants with moderate to severe Crohn’s disease, according to results from the GALAXI 2 & 3 trials at weeks 12 and 48. - Hormone-containing therapies may increase the risk of gut-brain disorders
A large-scale, retrospective study of 712,741 women found that hormone-containing contraceptives and hormone replacement therapy may be linked to irritable bowel syndrome and functional dyspepsia. - COX-2 inhibitors show promise in reducing the severity of acute pancreatitis
The efficacy and safety of cyclooxygenase-2 inhibitors were evaluated in a prospective, multicentre trial, which demonstrated a significant reduction in the occurrence and duration of severe acute pancreatitis. - STARS: Apraglutide shows efficacy in patients with SBS-IF
Apraglutide, a long-acting glucagon-like peptide-2 analogue, significantly reduced parenteral support volume in patients with short bowel syndrome with intestinal failure. Conducted across 73 centres in 18 countries, the trial confirmed the efficacy and safety of apraglutide in this population. - REGENERATE study: Obeticholic acid shows antifibrotic benefit in NASH
The phase 3 REGENERATE study of the farnesoid X receptor agonist obeticholic acid demonstrated significant antifibrotic benefits in patients with nonalcoholic steatohepatitis. - Promising data for cardiovascular outcomes of bariatric surgery in patients with obesity
Bariatric surgery was compared with glucagon-like peptide-1 receptor agonists in patients with obesity. Primary endpoints included incident heart failure, composite cardiovascular events, and composite cerebrovascular events. The results favoured the bariatric surgery option.
Enjoy Listening!
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Meet the Experts: Navigating Kidneys and Genes Next Article
Sulthiame may be the next treatment for OSA »
« Meet the Experts: Navigating Kidneys and Genes Next Article
Sulthiame may be the next treatment for OSA »
Table of Contents: DDW 2024
Featured articles
PREEMPT CRC: Blood-based screening test for colorectal cancer shows promise
Eosinophilic Oesophagitis Treatments and Outcomes
Mepolizumab improves the histologic severity of eosinophilic oesophagitis
Budesonide demonstrates efficacy in eosinophilic oesophagitis
Dupilumab shows promising results in treating paediatric eosinophilic oesophagitis
Quality-of-life assessment in children with eosinophilic oesophagitis
Gut-Brain Axis and Neurological Disorders
Gut permeability and neuroinflammation linked in Parkinson’s disease
Cardiovascular and Metabolic Health Innovations
Promising data for cardiovascular outcomes of bariatric surgery in patients with obesity
Inflammatory Bowel Disease Therapies
GALAXI 2 & 3: Guselkumab proves efficacy in Crohn’s disease
QUASAR maintenance study: Guselkumab effective and safe for UC
VEDOKIDS: Vedolizumab maintains remission in patients with paediatric IBD
ADMIRE-CD II: Darvadstrocel does not meet primary endpoint in complex Crohn’s perianal fistulas
Advances in Endoscopy and Screening Techniques
PREEMPT CRC: Blood-based screening test for colorectal cancer shows promise
New cable-transmission capsule endoscopy shows high accuracy in detecting upper GI lesions
Liver and Biliary Tract Diseases Updates
Superior OS with atezolizumab plus bevacizumab versus lenvatinib in unresectable HCC
Nutritional consultation boosts nutritional status in patients with alcohol-associated hepatitis
REGENERATE study: Obeticholic acid shows antifibrotic benefit in NASH
Acalculous cholecystitis as a risk factor for gallbladder perforation: insights from a 10-year retrospective study
Other Gastrointestinal Diseases
STARS: Apraglutide shows efficacy in short bowel syndrome with intestinal failure
COX-2 inhibitors show promise in reducing severity of acute pancreatitis
Hormone-containing therapies may increase the risk of IBS and functional dyspepsia
Related Articles
June 13, 2023
IBS management: the complex role of dietary fibres
December 7, 2023
Digital intervention relieves symptoms and improves QoL in IBS
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com